Wall Street analysts forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce earnings of $0.07 per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings. The highest EPS estimate is $0.12 and the lowest is $0.02. Vanda Pharmaceuticals reported earnings per share of $0.20 during the same quarter last year, which would suggest a negative year over year growth rate of 65%. The firm is scheduled to report its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $0.32 per share for the current year, with EPS estimates ranging from $0.27 to $0.35. For the next financial year, analysts forecast that the firm will post earnings of $0.82 per share, with EPS estimates ranging from $0.20 to $1.75. Zacks’ EPS averages are an average based on a survey of analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The company had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. During the same quarter in the prior year, the firm earned $0.15 earnings per share. Vanda Pharmaceuticals’s revenue was up 24.7% on a year-over-year basis.

Several analysts have recently weighed in on VNDA shares. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Friday, August 2nd. Oppenheimer set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, May 5th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $26.57.

In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 2,575 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total value of $37,826.75. Following the sale, the senior vice president now owns 57,425 shares of the company’s stock, valued at approximately $843,573.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total transaction of $1,117,856.48. Following the completion of the sale, the chief executive officer now directly owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The disclosure for this sale can be found here. 8.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in VNDA. United Services Automobile Association boosted its position in shares of Vanda Pharmaceuticals by 5.8% during the second quarter. United Services Automobile Association now owns 14,544 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 792 shares during the last quarter. Voloridge Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 16.8% during the second quarter. Voloridge Investment Management LLC now owns 57,793 shares of the biopharmaceutical company’s stock worth $814,000 after acquiring an additional 8,310 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in shares of Vanda Pharmaceuticals by 28.0% during the second quarter. Pictet Asset Management Ltd. now owns 476,000 shares of the biopharmaceutical company’s stock worth $6,707,000 after acquiring an additional 104,200 shares during the last quarter. Nuveen Asset Management LLC bought a new position in shares of Vanda Pharmaceuticals during the second quarter worth $13,388,000. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Vanda Pharmaceuticals by 89.1% during the second quarter. UBS Asset Management Americas Inc. now owns 34,327 shares of the biopharmaceutical company’s stock worth $484,000 after acquiring an additional 16,171 shares during the last quarter. 99.33% of the stock is currently owned by hedge funds and other institutional investors.

Shares of VNDA traded up $0.28 during midday trading on Friday, hitting $15.19. The stock had a trading volume of 525,000 shares, compared to its average volume of 893,224. Vanda Pharmaceuticals has a 1 year low of $11.83 and a 1 year high of $33.44. The firm has a market cap of $794.31 million, a PE ratio of 31.65 and a beta of 0.38. The stock’s 50 day moving average is $13.91 and its 200 day moving average is $16.65.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Story: Holder of Record

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.